Research Reports

Key takeaways

Board appointed Charles Q. Morris, M.D., age 61, as Chief Medical Officer effective April 20, 2026.

Initial annual base salary of $535,000 with target bonus up to 40%.

Option award for 450,000 shares under 2020 Equity Incentive Plan vesting over four years.

Prior roles: CMO at Lava Therapeutics (2023-2025), Celyad Oncology (2021-2023), Radius Health (2018-2020).

Severance: 9 months base salary and benefits without Cause/Good Reason; 12 months post-Change in Control.

No family relationships or conflicting arrangements disclosed.

Full analysis

Prelude Therapeutics strengthens its leadership with the appointment of Charles Q. Morris, M.D., an experienced oncology executive, as Chief Medical Officer effective April 20, 2026. Dr. Morris brings over 30 years of drug development expertise, including CMO roles at Lava Therapeutics, Celyad Oncology, and Radius Health, where he contributed to approvals like ONSERDU for breast cancer. Compensation includes a competitive $535,000 base salary, 40% target bonus, and a significant 450,000-share option grant vesting quarterly over four years. Enhanced severance terms post-Change in Control provide retention incentives. This hire aligns with advancing lead programs in myeloproliferative neoplasms and ER+ breast cancer into clinical development in 2026, positioning the company for execution amid its precision oncology pipeline.

PRLD · Prelude Therapeutics Incorporated

Summary

Key takeaways

Full analysis